Aduro Biotech to Present at the H.C. Wainwright Global Life Sciences Conference
April 01 2019 - 7:00AM
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T.
Isaacs, chairman, president and chief executive officer of Aduro,
is scheduled to present at the H.C. Wainwright Global Life Sciences
Conference in London, United Kingdom on Monday, April 8th at 9:30
am GMT.
To access the live webcasts and subsequent archived recordings
of these and other company presentations, please visit the investor
section of Aduro's website at www.aduro.com. The archived webcasts
will remain available for replay on Aduro’s website for 30
days.
About Aduro Aduro Biotech, Inc. is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of therapies that are designed to
harness the body's natural immune system for the treatment of
patients with challenging diseases. Aduro’s product candidates in
the Stimulator of Interferon Genes (STING) and A Proliferation
Inducing Ligand (APRIL) pathways are being investigated in cancer,
autoimmune and inflammatory diseases. ADU-S100 (MIW815), which
potentially activates the intracellular STING receptor for a potent
tumor-specific immune response, is being evaluated in patients with
cutaneously accessible metastatic solid tumors or lymphomas.
BION-1301, a fully blocking monoclonal antibody that blocks APRIL
binding to both the BCMA and TACI receptors, is being evaluated in
multiple myeloma and as a potential treatment for IgA nephropathy.
Aduro is collaborating with a number of leading global
pharmaceutical companies to help expand and drive its product
pipeline. For more information, please visit www.aduro.com.
Investor Relations
Contact: |
Media
Contact: |
Noopur
Liffick |
Aljanae
Reynolds |
510-809-2465 |
510-809-2452 |
investors@aduro.com |
press@aduro.com |
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Aduro Biotech Inc (NASDAQ): 0 recent articles
More News Articles